The report on Eli Lilly and Company was published on April 11, 2026. Share the report or generate your own report on Finsight Alpha.

Eli Lilly and Company logo

Eli Lilly and Company

Neutral
Ticker: LLY · https://www.lilly.com

Executive Summary

Eli Lilly and Company's recent decline in market share in India's weight-loss drug market raises significant concerns about its competitive position. The company's share fell from 61 percent to 56 percent in March 2026, coinciding with the entry of generic competitors. This shift not only highlights the challenges Eli Lilly faces in maintaining its dominance but also underscores the broader risks posed by an increasingly crowded market.

While Eli Lilly reports strong revenue and EBITDA growth, with figures reaching $65.18 billion and $27.94 billion respectively for FY2025, its high price-to-earnings ratio of 40.88 suggests potential overvaluation. This could deter investors looking for value, especially in a market where operational inefficiencies are becoming apparent. Rising working capital metrics indicate that the company is tying up more resources, which may impact cash flow and operational efficiency. Furthermore, the current economic environment, characterized by inflation and tighter healthcare budgets, complicates Eli Lilly's growth outlook.

In summary, Eli Lilly and Company is navigating a challenging landscape marked by competitive pressures and operational inefficiencies. Investors should approach with caution, given the potential risks overshadowing the company's growth narrative. The overall assessment remains Neutral.

Next reported earnings: Thursday, 30 April 2026, before market open.

Eli Lilly and Company 6-Month Share Price

Key Metrics

Market Cap $887.63 B i
6-Month Share Price Change 12.72% i
Revenue (TTM) $65.18 B i
EBITDA (TTM) $27.94 B i
EPS (TTM) $22.98 i
Operating Cash Flow (TTM) $16.81 B i
Free Cash Flow (TTM) $8.97 B i
Cash and cash equivalents $7.16 B i
P/E Ratio (TTM) 40.88 i
Price/Book (TTM) 31.79 i
Debt/Equity 1.60 i
Current Ratio 1.58 i
Dividend Yield (TTM) 0.66% i

Tap or click the i icon for a metric definition.

The Eli Lilly and Company Story

Founded in 1876 and headquartered in Indianapolis, Eli Lilly and Company has established itself as a leader in the pharmaceutical industry. The company focuses on developing innovative medicines in areas such as diabetes, oncology, immunology, and neurodegeneration. Over the years, Lilly has achieved significant milestones, including the introduction of insulin in the 1920s, which transformed diabetes management, and the launch of the first antidepressant, Prozac, in the late 1980s.

In recent years, Lilly has pivoted towards biotechnology, investing heavily in research and development to create biologic therapies. This shift has paid off, with the successful launch of drugs like Trulicity for diabetes and Taltz for psoriasis. However, the company faces challenges, including patent expirations and increasing competition in the biopharmaceutical space. Taken together, these factors highlight Lilly's commitment to innovation while navigating a complex market landscape.

Macro Industry Position

The US listing is crucial for the healthcare sector, particularly for drug manufacturers, as it provides access to a large and diverse market. The Drug Manufacturers - General industry includes key players such as Pfizer, Merck, and Johnson & Johnson. These companies compete in a landscape shaped by innovation, regulatory scrutiny, and the need for effective reimbursement strategies. The US market's size and complexity often dictate how companies fund their operations and develop new products, making it a focal point for industry dynamics.

Eli Lilly and Company differentiates itself through its focus on innovative therapies for chronic conditions, particularly in diabetes and oncology. While competitors like AbbVie and Bristol-Myers Squibb also target these areas, Lilly's recent advancements in biologic therapies, such as Trulicity and Taltz, highlight its commitment to addressing unmet medical needs. This focus on innovation not only strengthens its product portfolio but also positions Lilly favorably against rivals, especially as the industry shifts towards more personalized medicine.

The current macro environment presents both challenges and opportunities for Eli Lilly and the broader drug manufacturing sector. With consumer prices rising, healthcare budgets are under pressure, impacting payer reimbursement strategies. As employment costs increase, companies must navigate tighter margins while investing in research and development. Regulatory risks also loom large, as changes in policy can affect drug approval processes and market access. Overall, the demand for innovative therapies remains strong, driven by an aging population and the prevalence of chronic diseases.

Rising consumer prices are tightening household budgets, which directly impacts spending on healthcare and pharmaceuticals. The Fed-funds rate remains steady at 3.64 percent, influencing borrowing costs for companies like Eli Lilly and Company as they seek funding for research and development. US inflation is currently at 3.3 percent year over year, which pressures both consumer and corporate healthcare expenditures. Meanwhile, the US 10-year yield stands at 4.29 percent, affecting long-term financing strategies for drug manufacturers as they navigate capital markets to support innovation and growth.

Bottom line: Eli Lilly and Company operates in a challenging environment marked by inflationary pressures and steady interest rates, which complicate funding for research and development. The company's focus on innovative therapies positions it well against competitors, but the ongoing economic landscape necessitates careful management of costs and strategic investments to maintain its competitive edge in the drug manufacturing sector.

Recent Developments

Eli Lilly and Company (LLY) faced a decline in its market share in India's weight-loss drug market, dropping to 56% in March from 61% in February 2026. This decrease occurred as generic versions of semaglutide entered the market, which posed a challenge to Eli Lilly's position. In contrast, Novo Nordisk maintained its market share at 25% during the same period, indicating a competitive landscape for weight-loss medications in India.[1]

On April 7, 2026, Representative Gilbert Ray Cisneros, Jr. disclosed the sale of shares in Eli Lilly and Company. The transaction, which took place on March 13, involved the sale of stock valued between $1,001 and $15,000. This sale was part of a series of trades made by the Representative, which included a purchase of stock valued at $15,001.[2]

Eli Lilly's CEO stated on April 7, 2026, that the company was ready to scale production of its weight-loss pill. This announcement came amid increasing competition in the obesity drug market, particularly from Novo Nordisk. The CEO's comments suggested a proactive approach to meet anticipated demand for the product as the company sought to strengthen its market position.[3]

For investors, these updates highlight a mixed scenario for Eli Lilly. The company's readiness to increase production of its weight-loss pill may position it favorably in a competitive market. However, the decline in market share in India raises concerns about its ability to maintain dominance in key regions. Investors should monitor these developments closely as they could impact Eli Lilly's future performance and market strategy.[4][5][6]

Sources

  • [1] Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India (Apr 10, 2026)
  • [2] Rep. Gilbert Ray Cisneros, Jr. Sells Eli Lilly and Company (NYSE:LLY) Shares (Apr 10, 2026)
  • [3] Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill - TipRanks (Apr 7, 2026)
  • [4] 3 Reasons To Buy Eli Lilly Now (NYSE:LLY) - Seeking Alpha (Apr 8, 2026)
  • [5] Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead: report (LLY:NYSE) - Seeking Alpha (Apr 9, 2026)
  • [6] This Strategy Pays You 9.2% While Lining Up LLY at Bargain Prices - Trefis (Apr 11, 2026)

Financial Deep-Dive

Welcome to the Financial Deep-Dive. The eight tabs below organise Eli Lilly and Company's financial data into valuation, profitability, per-share data, leverage, liquidity, efficiency, working-capital, and R&D. Each tab presents financial metrics and trend charts for its category, along with key strengths and weaknesses. Click on any measure for a clear definition and insight into its relevance for investors. At the bottom, you'll find a detailed Financial Health Summary outlining Eli Lilly and Company's financial condition based on their most recent accounts.

Valuation and Market Multiples

  • Market capitalization: $887.63 B (status: green)
  • Price-to-earnings ratio: 40.88 (status: red)
  • Price-to-sales ratio: 13.62 (status: red)
  • Price-to-book ratio: 31.79 (status: red)
  • Enterprise-value/EBITDA multiple: 33.04 (status: red)
  • EV-to-operating-cash-flow: 54.90 (status: red)
  • EV-to-free-cash-flow: 102.87 (status: red)
  • Earnings yield: 2.45% (status: green)

Profitability Ratios

  • Net profit margin: increased over the period (status: green)
  • Return on equity (ROE): increased over the period (status: green)
  • Operating profit margin: increased over the period (status: green)
  • Gross profit margin: increased over the period (status: green)
  • Return on assets (ROA): increased over the period (status: green)
  • Return on capital employed (ROCE): increased over the period (status: green)
  • Pretax profit margin: increased over the period (status: green)
  • Return on invested capital (ROIC): increased over the period (status: green)
  • Income quality: decreased over the period (status: red)
  • Return on tangible assets: increased over the period (status: green)

Per-Share and Key Metrics

  • Earnings per share (EPS): $22.98 (status: green)
  • Revenue per share: increased over the period (status: green)
  • Operating cash flow per share: increased over the period (status: green)
  • Free cash flow per share: increased over the period (status: green)
  • Cash per share: $8.09 (status: red)
  • Book value per share: $29.55 (status: green)
  • Tangible book value per share: $15.72 (status: green)
  • Interest-bearing debt per share: $47.33 (status: red)
  • Payout ratio: 26.09% (status: green)
  • Dividend per share: $6.23 (status: green)
  • Dividend yield: 0.66% (status: green)

Leverage and Coverage Ratios

  • Debt-to-equity ratio: 1.60 (status: amber)
  • Debt ratio: 0.38 (status: green)
  • Interest coverage: 37.34 (status: green)
  • Total debt to capitalization: 0.62 (status: amber)
  • Long-term debt to capitalization: 0.61 (status: red)
  • Cash-flow-to-debt ratio: 0.40 (status: green)

Liquidity Ratios

  • Cash and cash equivalents: $7.16 B (status: green)
  • Current ratio: 1.58 (status: amber)
  • Quick ratio: 1.19 (status: amber)
  • Cash ratio: 0.20 (status: red)

Activity and Efficiency Ratios

  • Asset turnover: increased over the period (status: green)
  • Receivables turnover: decreased over the period (status: red)
  • Inventory turnover: decreased over the period (status: red)
  • Payables turnover: decreased over the period (status: red)
  • Fixed-asset turnover: decreased over the period (status: red)
  • Operating cash flow-to-sales ratio: decreased over the period (status: red)
  • Free cash flow-to-operating cash flow ratio: increased over the period (status: green)

Working-Capital and Cycle Metrics

  • Cash conversion cycle: decreased over the period (status: green)
  • Days of sales outstanding: decreased over the period (status: green)
  • Days of inventory outstanding: decreased over the period (status: green)
  • Days of payables outstanding: decreased over the period (status: red)
  • Operating cycle: decreased over the period (status: green)

Capital-Intensity and R&D

  • R&D expense-to-revenue ratio: decreased over the period (status: green)
  • Capital expenditure-to-revenue ratio: increased over the period (status: red)
  • Capex-to-operating-cash-flow ratio: increased over the period (status: red)
  • Capex per share: increased over the period (status: red)
  • Capex-to-depreciation ratio: increased over the period (status: red)
  • Stock-based compensation-to-revenue ratio: decreased over the period (status: green)

Financial Health Summary

Eli Lilly and Company reported impressive financial growth for FY2025, with revenue reaching $65.18 billion, a significant increase from $45.04 billion in FY2024. The company's EBITDA also saw substantial growth, climbing to $27.94 billion from $15.23 billion the previous year. In the latest quarter, Eli Lilly generated $19.29 billion in revenue and $8.39 billion in EBITDA, supported by a robust operating cash flow of $16.81 billion.

The company's market capitalization stands at $887.63 billion, reflecting strong investor confidence. However, several valuation multiples raise concerns. The price-to-earnings ratio is at 40.88, while the price-to-sales and price-to-book ratios are 13.62 and 31.79, respectively. These figures suggest that Eli Lilly's stock may be overvalued relative to its earnings and sales. On a positive note, the company maintains a solid liquidity position with $7.16 billion in cash and cash equivalents, which supports its ability to meet short-term obligations despite a cash ratio of 0.20.

Despite the strong cash flow performance, Eli Lilly faces challenges in working capital management. The cash conversion cycle has increased, indicating that the company is tying up more days in working capital, which can hinder operational efficiency. Days of inventory outstanding have also risen, suggesting that inventory management may need attention. Additionally, days of payables outstanding have increased, indicating that suppliers are being paid more slowly, which could impact supplier relationships and future negotiations.

Verdict: Eli Lilly and Company demonstrates strong revenue and EBITDA growth, but rising working capital metrics present potential risks. Investors should monitor these trends closely as they could affect the company's operational efficiency and cash flow management.

Risks and Concerns

Investors should be wary of Eli Lilly and Company's recent decline in market share within the weight-loss drug sector, dropping from 61 percent to 56 percent in India as of March 2026. This shift coincides with the introduction of generic versions of semaglutide, which have intensified competition. While the company plans to scale production of its weight-loss pill, the effectiveness of this strategy remains uncertain against established competitors like Novo Nordisk, which maintained a 25 percent market share during the same period.

Operational challenges extend beyond market share. Eli Lilly's cash conversion cycle has increased, indicating that the company is taking longer to convert its investments in inventory and receivables back into cash. This trend, coupled with rising days of inventory outstanding, suggests potential inefficiencies in inventory management. If these issues persist, they could strain Eli Lilly's operational capabilities and hinder its ability to respond swiftly to market demands.

For shareholders, the financial metrics present a mixed picture. While Eli Lilly reported revenue growth to $65.18 billion for FY2025, its price-to-earnings ratio of 40.88 raises concerns about overvaluation. The company's liquidity position is solid, with $7.16 billion in cash, but the increasing working capital metrics could signal deeper issues. Investors must weigh these operational risks against the backdrop of a competitive landscape, as continued losses in market share could significantly impact future profitability and stock performance.

Outlook

Eli Lilly and Company faces a pivotal moment as it navigates a competitive landscape, particularly in the weight-loss drug market. The recent decline in market share in India, dropping to 56 percent, underscores the urgency for the company to enhance its production capabilities. The CEO's commitment to scaling production of its weight-loss pill signals a proactive strategy to reclaim lost ground. However, the entry of generic alternatives poses a significant threat, and how effectively Lilly can respond will be crucial for its market position.

Investors should remain vigilant as Eli Lilly works to bolster its competitive edge. The company's focus on innovative therapies has historically set it apart, yet the current economic environment, characterized by rising consumer prices and tighter healthcare budgets, complicates its path forward. Monitoring the company's ability to adapt to these pressures while maintaining its commitment to research and development will be essential. Future announcements regarding production scaling and market strategies will provide insight into whether Eli Lilly can sustain its leadership in a rapidly evolving market.

Red & Green Flags

This section distills all of the report's positives (green flags), negatives (red flags) and open questions (unknowns) into one place. The Overall view reflects a read of the evidence across the full report; it is not a simple tally of the lists below.

Green Flags

  • Eli Lilly has a strong market capitalization of $887.63 billion, reflecting investor confidence.
  • The company reported impressive revenue growth, reaching $65.18 billion for FY2025, up from $45.04 billion in FY2024.
  • Eli Lilly's EBITDA increased significantly to $27.94 billion from $15.23 billion year over year.
  • The net profit margin, return on equity, operating profit margin, gross profit margin, return on assets, return on capital employed, pretax profit margin, and return on invested capital all increased over the period.
  • Earnings per share (EPS) stands at $22.98, indicating strong profitability.
  • The company maintains a solid liquidity position with $7.16 billion in cash and cash equivalents.
  • The cash conversion cycle decreased, indicating improved efficiency in working capital management.
  • The CEO's commitment to scaling production of the weight-loss pill suggests a proactive approach to market challenges.

Red Flags

  • Eli Lilly's price-to-earnings ratio is at 40.88, raising concerns about potential overvaluation.
  • The company experienced a decline in market share in India's weight-loss drug market, dropping from 61 percent to 56 percent.
  • The introduction of generic versions of semaglutide has intensified competition, threatening Eli Lilly's market position.
  • The cash conversion cycle has increased, indicating inefficiencies in converting investments back into cash.
  • Days of inventory outstanding have risen, suggesting potential issues in inventory management.
  • Days of payables outstanding have increased, which could strain supplier relationships.
  • The company's income quality decreased over the period.

Unknowns

  • The effectiveness of Eli Lilly's strategy to scale production of its weight-loss pill against competitors remains uncertain.
  • The impact of rising consumer prices and tighter healthcare budgets on Eli Lilly's future performance is unclear.
  • Future announcements regarding production scaling and market strategies will determine if Eli Lilly can sustain its leadership.

8 green flags, 7 red flags, 3 unknowns.

Overall view: Neutral.

Why this view:

  • Eli Lilly's recent decline in market share in India's weight-loss drug market raises concerns about its competitive position.
  • The company's high price-to-earnings ratio suggests potential overvaluation, which could deter investors.
  • While revenue and EBITDA growth are strong, increasing working capital metrics indicate operational inefficiencies that could impact cash flow.
  • The competitive landscape, particularly with the entry of generics, poses significant risks to Eli Lilly's market dominance.
  • The current economic environment, marked by inflation and tighter healthcare budgets, complicates the company's growth outlook.

Action Checklist

Below are the next research steps a retail investor should consider based on this report.

Disclaimer

This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.